By Connor Hart
Shares of Iovance Biotherapeutics climbed after the company's treatment for certain types of skin cancer received market authorization in Canada.
The stock rose 20% to $3 in premarket trading Tuesday. Through Monday's close, shares have lost more than three-quarters of their value in the past year.
The biotechnology company said late Monday that Health Canada issued a Notice of Compliance with Conditions for its treatment, Amtagvi, for adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy.
"This approval in Canada is our first marketing authorization outside the U.S. and marks a significant step forward for Iovance as we prepare to introduce Amtagvi in countries with a high prevalence of advanced melanoma and address substantial unmet needs in solid tumor cancers," interim Chief Executive Frederick Vogt said.
He added that the company plans to authorize its first Canadian treatment center in the coming months, as it continues to advance its strategy for Amtagvi in additional markets.
Health Canada's approval was granted based on safety and efficacy results from a recent Phase 2 study.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 19, 2025 06:40 ET (10:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.